MK-7128, a novel CB1 receptor inverse agonist, improves scopolamine-induced learning and memory deficits in mice

Behavioural Pharmacology

Volumn 22, Issue 2, 2011, Pages 91-100

  Dillon, Gregory M ^a   Lubbers, Laura S ^b   Ferguson, Mitchell T ^a   Lao, Julie Z ^c   Huang, Ruey Ruey C ^c   Xiao, Jing C ^c   Fong, Tung M ^c,f   Hale, Jeffrey J ^d   Rupprecht, Kathleen ^d   Miao, Shouwu ^d   Rowe, Blake A ^b   Kornecook, Thomas J ^a,g   Dodart, Jean Cosme ^a,e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MRL   (United States)

^c Metabolic Disorders ^*  (United States)

^d MRL   (United States)

^e The Harvard Center for Neurodegeneration & Repair   (United States)

^f FOREST RESEARCH INSTITUTE   (United States)

^g AMGEN INC   (United States)

Author keywords

cannabinoids; CB1 receptor; cognition; mouse; receptor occupancy; scopolamine

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; MK 7128; SCOPOLAMINE; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; HABITUATION; HIPPOCAMPUS; LEARNING DISORDER; MALE; MEMORY; MOUSE; NONHUMAN;

ANIMALS; AZETIDINES; CEREBRAL CORTEX; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; OXADIAZOLES; PIPERIDINES; PROTEIN BINDING; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SCOPOLAMINE;

EID: 79952990094     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283423d7e     Document Type: Article

References (64)

1. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, et al. (2008). The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78.
2. Aigner TG (1988). Delta-9-tetrahydrocannabinol impairs visual recognition memory but not discrimination learning in rhesus monkeys. Psychopharmacol 95:507-511.
3. Anzalone S, Roland J, Vogt B, Savage L (2009). Acetylcholine efflux from retrosplenial areas and hippocampal sectors during maze exploration. Behav Brain Res 201:272-278.
4. Bannerman DM, Lemaire M, Beggs S, Rawlins JN, Iversen SD (2001). Cytotoxic lesions of the hippocampus increase social investigation but do not impair social-recognition memory. Exp Brain Res 138:100-109. (Pubitemid 32285351)
5. Bohme GA, Laville M, Ledent C, Parmentier M, Imperato A (2000). Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 95:5-7.
6. Chen C, Tonegawa S (1997). Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Annu Rev Neurosci 20:157-184. (Pubitemid 27106379)
7. Collins DR, Petwee RG, Davies SN (1995). Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br J Pharmacol 115:869-870.
8. Cosenza M, Gifford AN, Gatley SJ, Pyatt B, Liu Q, Makriyannis A, Volkow ND (2000). Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 38:477-482.
9. Degroot A, Köfalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N, et al. (2006). CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol 4:1236-1245. (Pubitemid 44435975)
10. Dember WM, Fowler H (1958). Spontaneous alternation behavior. Psychol Bull 55:412-428.
11. 125/131I]AM2233. Synapse 60:93-101. (Pubitemid 43878117)
12. Dillon GM, Qu X, Marcus JN, Dodart JC (2008). Excitotoxic lesions restricted to the dorsal CA1 field of the hippocampus impair spatial memory and extinction learning in C57BL/6 mice. Neurobiol Learn Mem 2:426-433.
13. Dodart JC, Mathis C, Ungerer A (1997). Scopolamine-induced deficits in a two-trial object recognition task in mice. Neuroreport 8:1173-1178. (Pubitemid 27198592)
14. Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. (2007). Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl] -2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 321:1013-1022. (Pubitemid 46762708)
15. Fong TM, Shearman LP, Stribling DS, Shu J, Lao J, Huang CRR, et al. (2009). Pharmacological efficacy and safety profile of taranabant in preclinical species. Drug Dev Res 70:349-362.
16. Friedman E, Hanin I, Gershon S (1976). Effect of tetrahydrocannabinols on 3H-acetylcholine biosynthesis in various rat brain slices. J Pharmacol Exp Ther 196:339-345.
17. 123I-labeled AM251: a radioiodinated ligand, which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 307:331-338. (Pubitemid 26233375)
18. Gessa GL, Casu MA, Carta G, Mascia MS (1998). Cannabinoids decrease acetylcholine release in the medial prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 355:119-124. (Pubitemid 28404693)
19. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND (1999). Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483. (Pubitemid 29119654)
20. 125I]L-775-219. J Labelled Cpd Radiopharm 44:55-59. (Pubitemid 32059712)
21. Hasselmo ME (2006). The role of acetylcholine in learning and memory. Curr Opin Neurobiol 16:710-715. (Pubitemid 44791918)
22. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in-vitro autoradiographic study. J Neurosci 11:563-583.
23. Hölter SM, Kallnik M, Wurst W, Marsicano G, Lutz B, Wotjak CT (2005). Cannabinoid CB1 receptor is dispensable for memory extinction in an appetitively-motivated learning task. Eur J Pharmacol 510:69-74. (Pubitemid 40312391)
24. Isseroff A (1979). Limited recovery of spontaneous alternation after extensive hippo-campal damage: evidence for a memory impairment. Exp Neurol 64:284-294. (Pubitemid 9176391)
25. Iversen SD (1997). Behavioural evaluation of cholinergic drugs. Life Sciences 60:1145-1152. (Pubitemid 27165587)
26. Janero DR, Makriyannis A (2009). Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 14:43-65.
27. Kathmann M, Weber B, Zimmer A, Schlicker E (2001). Enhanced acetylcholine release in the hippocampus of cannabinoid CB1 receptor-deficient mice. Br J Pharmacol 132:1169-1173. (Pubitemid 32234698)
28. Kimble DP (1975). Choice behavior in rats with hippocampal lesions. In: Isaacson RL, Pribram KH, editors. The hippocampus, neurophysiology and behavior. New York: Plenum Press. pp. 309-326.
29. Kirkham TC, Tucci SA (2006). Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 5:272-292.
30. Lagalwar S, Bordayo EZ, Hoffmann KL, Fawcett JR, Frey WH II (1999). Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci 13:55-61. (Pubitemid 30102000)
31. Lalonde R (2002). The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26:91-104. (Pubitemid 34130537)
32. Lafenêtre P, Chaouloff F, Marsicano G (2007). The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 56:367-381. (Pubitemid 350026395)
33. Le Foll B, Gorelick DA, Goldberg SR (2009). The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacol 205:171-174.
34. Lichtman AH, Cravatt BF (2005). Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 115:1130-1133. (Pubitemid 40629027)
35. Lichtman AH, Dimen KR, Martin BR (1995). Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacol 119:282-290.
36. López-Moreno JA, González-Cuevas G, Moreno G, Navarro M (2008). The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol 13:160-187. (Pubitemid 351692981)
37. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534. (Pubitemid 34851398)
38. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
39. Miller LL, Branconnier RJ (1983). Cannabis: effects on memory and the cholinergic limbic system. Psychol Bull 93:441-456.
40. Misner DL, Sullivan JM (1999). Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 19:6795-6805. (Pubitemid 29380108)
41. Mumby DG (2001). Perspectives on object recognition memory following hippo-campal damage: lessons from studies in rats. Behav Brain Res 127:159-181. (Pubitemid 33062408)
42. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65. (Pubitemid 23305569)
43. Need AB, Davis RJ, Alexander-Chacko JT, Eastwood B, Chernet E, Phebus LA, et al. (2006). The relationship of in-vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacol 184:26-35. (Pubitemid 43005754)
44. Niyuhire F, Varvel SA, Thorpe AJ, Stokes RJ, Wiley JL, Lichtman AH (2007). The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. Psychopharmacology 191:223-231. (Pubitemid 46354610)
45. Reibaud M, Obinu MC, Ledent C, Parmentier M, Böhme GA, Imperato A (1999). Enhancement of memory in cannabinoid CB1 receptor knockout mice. Eur J Pharmacol 379:R1-R2. (Pubitemid 29492956)
46. Sain NM, Liang A, Kane SA, Urban MO (2009). Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55 940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain. Neuropharmacol 57:235-241.
47. Schlicker E, Kathmann M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572. (Pubitemid 33042646)
48. Shearman LP, Stribling DS, Camacho RE, Rosko KM, Wang J, Tong S, et al. (2008). Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, imidazole 24b, in rodents. Eur J Pharmacol 579:215-224.
49. Squires AS, Peddle R, Milway SJ, Harley CQ (2006). Cytotoxic lesions of the hippocampus do not impair social recognition memory in socially housed rats. Neurobiol Learn Mem 85:95-101. (Pubitemid 41786054)
50. Stevens R (1973). Effects of duration of sensory input and intertrial interval on spontaneous alternation in rats with hippocampal lesions. Physiol Psychol 1:41-44.
51. Sullivan JM (2000). Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learn Mem 7: 132-139. (Pubitemid 30407778)
52. Suzuki A, Josselyn SA, Frankland PW, Masushige S, Silva AJ, Kida S (2004). Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci 19:4787-4795. (Pubitemid 38668203)
53. Taber RA, Hayman LA, Hurley KH (2009). Endocannabinoids: stress, anxiety, and fear. J Neuropsychiatry Clin Neurosci 21:108-113.
54. Takahashi RN, Pamplona FA, Fernandes MS (2005). The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380:270-275. (Pubitemid 40616094)
55. Tang Y, Aigner TG (1996). Release of cerebral acetylcholine increases during visually mediated behavior in monkeys. Neuroreport 7:2231-2235. (Pubitemid 26361852)
56. Terranova JP, Michaud FC, Le Fur G, Soubrie P (1995). Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol 352: 576-579.
57. Terranova JP, Storme JJ, Lafon N, Péàio A, Rinaldi-Carmona M, Le Fur G, Soubrié P (1996). Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacol 126:165-172. (Pubitemid 26246767)
58. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, et al. (2003). The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544-553. (Pubitemid 36315302)
59. Tzavara ET, Wade MR, Davis RJ, El Khoury MA, Nomikos GG (2008). Role of metabotropic glutamate receptor 5 in the procholinergic effects of neuropsychotherapeutic compounds. Synapse 62:940-943.
60. Varvel SA, Lichtman AH (2002). Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301:915-924. (Pubitemid 34595080)
61. Varvel SA, Wise LE, Lichtman AH (2009). Are CB(1) receptor antagonists nootropic or cognitive impairing agents? Drug Dev Res 70:555-565.
62. Warburton EC, Koder T, Cho K, Massey PV, Duguid G, Barker GR, et al. (2003). Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory. Neuron 38:987-996. (Pubitemid 36782388)
63. Wise LE, Iredale PA, Stokes RJ, Lichtman AH (2007). Combination of rimonabant and donepezil prolongs spatial memory duration. Neuropsychopharmacol 32:1805-1812. (Pubitemid 47076380)
64. Wolff MC, Leander JD (2003). SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. Eur J Pharmacol 477:213-217. (Pubitemid 38366393)